دورية أكاديمية
أعرض في EDS

The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status.

التفاصيل البيبلوغرافية
العنوان: The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status.
المؤلفون: Gatalica Z; Reference Medicine, Phoenix, Arizona, USA; The University of Oklahoma Health Sciences Center, Oklahoma, USA., Kuzmova N; Reference Medicine, Phoenix, Arizona, USA., Rose I; Reference Medicine, Phoenix, Arizona, USA., Ulamec M; Ljudevit Jurak Clinical Department of Pathology and Cytology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia; Department of Pathology and Scientific Group for Research on Epigenetic Biomarkers, University of Zagreb School of Medicine, Zagreb, Croatia., Peric-Balja M; Oncological Pathology Department, Ljudevit Jurak Clinical Department of Pathology and Cytology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia., Skenderi F; Department of Pathology, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina., Vranic S; College of Medicine, QU Health, Qatar University, Doha, Qatar.
المصدر: Biomolecules & biomedicine [Biomol Biomed] 2024 Mar 11; Vol. 24 (2), pp. 256-261. Date of Electronic Publication: 2024 Mar 11.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Association of Basic Medical Sciences of FBIH Country of Publication: Bosnia and Herzegovina NLM ID: 9918522188506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2831-090X (Electronic) Linking ISSN: 28310896 NLM ISO Abbreviation: Biomol Biomed Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Sarajevo : Association of Basic Medical Sciences of FBIH, [2023]-
مواضيع طبية MeSH: Carcinoma*/metabolism , Carcinoma, Skin Appendage*/metabolism , Skin Neoplasms*/metabolism, Female ; Humans ; Middle Aged ; Receptor, ErbB-2/genetics ; Lymphocytes, Tumor-Infiltrating ; Retrospective Studies
مستخلص: In the current study, we assessed the prevalence and molecular features of HER2-low phenotype in the apocrine carcinomas of the breast (ApoCa) and its relationship with tumor-infiltrating lymphocytes (TILs). A cohort of 64 well-characterized therapy-naïve ApoCa was used. The TIL distribution was assessed using the hematoxylin and eosin whole slide/scanned images following the international TILs working group recommendations. Next-generation sequencing (NGS) was performed in a subset of HER2-low ApoCa. All patients were women, with a mean age of 62 years. Forty-three carcinomas were pure apocrine carcinoma (PAC; ER-/AR+), and the remaining 21 were classified as apocrine-like carcinomas (ALCs; ER+/-, AR+/-). HER2/neu was positive (score 3+ by IHC and/or amplified by FISH) in 20/43 (47%) PAC and 4/21 (19%) ALC. The prevalence of HER2-low expression (scores 1+ or 2+ without HER2 amplification) in ApoCa was 39% without significant differences between PAC and ALC (P = 0.14); however, the HER2-low phenotype was more prevalent in triple-negative PAC than in ALC (P < 0.001). Levels of TILs were low (≤10%) in 74% of ApoCa (median 5%, range 0%-50%). TIL levels were significantly higher in ALC than in PAC (P = 0.02). HER2 status had no impact on TIL distribution (P = 0.45). The genomic profile of HER2-low ApoCa was similar to other subtypes of ApoCa. ApoCa has predominantly low TIL, particularly PAC. The prevalence of the HER2-low phenotype in ApoCa is high, which should have therapeutic and clinical implications given the recently approved therapies with antibody-drug conjugates (ADCs) for HER2-low breast cancers.
References: Clin Breast Cancer. 2020 Aug;20(4):326-331.e1. (PMID: 32197944)
Cancers (Basel). 2021 May 12;13(10):. (PMID: 34066060)
NPJ Breast Cancer. 2021 Dec 1;7(1):150. (PMID: 34853355)
Clin Breast Cancer. 2019 Apr;19(2):131-136. (PMID: 30268765)
Oncologist. 2022 Apr 5;27(4):e313-e327. (PMID: 35380716)
J Clin Oncol. 2020 Jun 10;38(17):1951-1962. (PMID: 32330069)
J Clin Oncol. 2019 Mar 1;37(7):559-569. (PMID: 30650045)
Hum Vaccin Immunother. 2021 Nov 2;17(11):4457-4466. (PMID: 34623225)
Hum Pathol. 2022 Nov;129:40-46. (PMID: 35998819)
JAMA Oncol. 2022 Aug 1;8(8):1177-1183. (PMID: 35737367)
N Engl J Med. 2022 Jul 7;387(1):9-20. (PMID: 35665782)
Histopathology. 1991 Nov;19(5):403-10. (PMID: 1757079)
Cancer Med. 2019 Dec;8(17):7322-7329. (PMID: 31609094)
Ann Oncol. 2015 Feb;26(2):259-71. (PMID: 25214542)
N Engl J Med. 2020 Feb 13;382(7):610-621. (PMID: 31825192)
JAMA Oncol. 2022 Apr 01;8(4):1-4. (PMID: 35113160)
J Clin Oncol. 2020 Apr 20;38(12):1346-1366. (PMID: 31928404)
Mod Pathol. 2020 Dec;33(12):2473-2482. (PMID: 32504034)
Clin Breast Cancer. 2022 Jun;22(4):e576-e585. (PMID: 35027319)
Pathol Res Pract. 1997;193(11-12):753-8. (PMID: 9521507)
Clin Breast Cancer. 2023 Aug;23(6):567-575. (PMID: 37336652)
J Immunother Cancer. 2016 Oct 18;4:59. (PMID: 27777769)
Am J Surg Pathol. 2016 Aug;40(8):1109-16. (PMID: 27259012)
Eur J Cancer. 2021 Sep;155:1-12. (PMID: 34311211)
Bosn J Basic Med Sci. 2017 Feb 21;17(1):9-11. (PMID: 28027454)
Cancers (Basel). 2023 Jan 26;15(3):. (PMID: 36765724)
Lancet Oncol. 2019 Jun;20(6):816-826. (PMID: 31047803)
JAMA Oncol. 2016 Oct 01;2(10):1354-1360. (PMID: 27355489)
NPJ Breast Cancer. 2021 Oct 12;7(1):137. (PMID: 34642348)
Bosn J Basic Med Sci. 2021 Feb 01;21(1):1-4. (PMID: 32530388)
Hum Pathol. 2015 Sep;46(9):1350-9. (PMID: 26208846)
Mod Pathol. 2010 May;23(5):644-53. (PMID: 20208479)
NPJ Breast Cancer. 2022 Jan 11;8(1):3. (PMID: 35017545)
Am J Surg Pathol. 2021 May 1;45(5):701-707. (PMID: 33739790)
Breast Cancer Res Treat. 2022 Jun;193(2):523-533. (PMID: 35355162)
Science. 2018 Feb 2;359(6375):582-587. (PMID: 29217585)
المشرفين على المادة: EC 2.7.10.1 (Receptor, ErbB-2)
تواريخ الأحداث: Date Created: 20231002 Date Completed: 20240314 Latest Revision: 20240627
رمز التحديث: 20240627
مُعرف محوري في PubMed: PMC10950344
DOI: 10.17305/bb.2023.9868
PMID: 37782562
قاعدة البيانات: MEDLINE
الوصف
تدمد:2831-090X
DOI:10.17305/bb.2023.9868